Table 3.
Subgroup analyses of recurrence and tumor response.
| Subgroup | No. of studies | No. of patients | Estimates (HR/OR) | Lower limit to upper limit | P‐value |
|---|---|---|---|---|---|
| DFS/RFS | |||||
| Hepatectomy | 12 | 3155 | 1.70 | 1.51–1.92 | < 0.001 |
| LDLT | 3 | 295 | 4.13 | 2.14–7.97 | < 0.001 |
| ORR | |||||
| Systemic therapy | 4 | 396 | 0.21 | 0.09–0.46 | < 0.001 |
| TACE | 2 | 265 | 0.70 | 0.28–1.72 | 0.434 |
| DCR | |||||
| Systemic therapy | 4 | 396 | 0.52 | 0.34–0.82 | 0.004 |
| TACE | 2 | 265 | 0.55 | 0.10–3.06 | 0.500 |
LDLT Living-Donor Liver Transplantation, TACE transarterial chemoembolization, DFS disease-free survival, RFS recurrence-free survival, ORR objective response rate, DCR disease control rates.